Evidence map›Paper›PMID 28291839›Full record

ArticlePloS one2017

Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging.

Andrew R Hoy, Martina Ly, Cynthia M Carlsson, Ozioma C Okonkwo, Henrik Zetterberg, Kaj Blennow, Mark A Sager, Sanjay Asthana, Sterling C Johnson, Andrew L Alexander and 1 more

Abstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. The effect of Alzheimer's disease genetic factors on limbic white matter microstructure.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  15. Article
  16. Review
  17. White Matter Injury in Central Nervous System Disorders.Neuropsychiatric disease and treatment · 2025
    Review
  18. Article
  19. Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrew R HoyLieutenant, Medical Service Corp, United States Navy, Falls Church, Virginia, United States of America.ORCID http://orcid.org/0000-0001-9254-8142
Martina LyGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.
Cynthia M CarlssonGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.
Ozioma C OkonkwoGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.
Henrik ZetterbergClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Mark A SagerWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, Wisconsin, United States of America.
Sanjay AsthanaGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.
Sterling C JohnsonGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.
Andrew L AlexanderDepartment of Medical Physics, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Barbara B BendlinGeriatric Research Education and Clinical Center, William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin, United States of America.

Funding

Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
The Longitudinal Course of Neural Function and Amyloid in People At Risk for ADR01AG021155 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sterling C Johnson · 2004 to 2026
$27.0M
WISCONSIN CENTER ON MENTAL RETARDATION: CORE SUPPORTP30HD003352 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI MESSING, ALBEE · 1985 to 2015
$25.2M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHAPPELL, RICHARD J · 2009 to 2018
$16.2M
Summer Research ExperienceP50MH100031 · NIMH · UNIVERSITY OF WISCONSIN-MADISON · PI KALIN, NED H · 2013 to 2017
$10.4M
Waisman Intellectual and Developmental Disabilities Research Center Down Syndrome RegistryU54HD090256 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI POLLAK, SETH D · 2016 to 2020
$6.0M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR56AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2017 to 2017
$759k
NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG037639NIA NIH HHS R56 AG037639NICHD NIH HHS P30 HD003352NICHD NIH HHS U54 HD090256NIMH NIH HHS P50 MH100031
6 · The paper itself

Abstract

Brain changes associated with Alzheimer's disease (AD) begin decades before disease diagnosis. While β-amyloid plaques and neurofibrillary tangles are defining features of AD, neuronal loss and synaptic pathology are closely related to the cognitive dysfunction. Brain imaging methods that are tuned to assess degeneration of myelinated nerve fibers in the brain (collectively called white matter) include diffusion tensor imaging (DTI) and related techniques, and are expected to shed light on disease-related loss of structural connectivity. Participants (N = 70, ages 47-76 years) from the Wisconsin Registry for Alzheimer's Prevention study underwent DTI and hybrid diffusion imaging to determine a free-water elimination (FWE-DTI) model. The study assessed the extent to which preclinical AD pathology affects brain white matter. Preclinical AD pathology was determined using cerebrospinal fluid (CSF) biomarkers. The sample was enriched for AD risk (APOE ε4 and parental history of AD). AD pathology assessed by CSF analyses was significantly associated with altered microstructure on both DTI and FWE-DTI. Affected regions included frontal, parietal, and especially temporal white matter. The f-value derived from the FWE-DTI model appeared to be the most sensitive to the relationship between the CSF AD biomarkers and microstructural alterations in white matter. These findings suggest that white matter degeneration is an early pathological feature of AD that may have utility both for early disease detection and as outcome measures for clinical trials. More complex models of microstructural diffusion properties including FWE-DTI may provide increased sensitivity to early brain changes associated with AD over standard DTI.

Indexed as

AgedAlzheimer DiseaseDiffusion Tensor ImagingFemaleHumansMaleMiddle AgedWhite Matter

Identifiers

PMID28291839
PMCPMC5349685

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.